Identification of 2‑Sulfonyl/Sulfonamide Pyrimidines as Covalent Inhibitors of WRN Using a Multiplexed High-Throughput Screening Assay

• Published in: Biochemistry (Easton) Vol. 62; no. 14; pp. 2147 - 2160
• Main Authors: Parker, Mackenzie J., Lee, Hyelee, Yao, Shihua, Irwin, Sean, Hwang, Sunil, Belanger, Kylie, de Mare, Sofia Woo, Surgenor, Richard, Yan, Lu, Gee, Patricia, Morla, Shravan, Puyang, Xiaoling, Hsiao, Peng, Zeng, Hao, Zhu, Ping, Korpal, Manav, Dransfield, Paul, Bolduc, David M., Larsen, Nicholas A.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 18-07-2023
• Subjects: Exodeoxyribonucleases - genetics; High-Throughput Screening Assays; Humans; Microsatellite Instability; Neoplasms; RecQ Helicases - genetics; RecQ Helicases - metabolism; Werner Syndrome; Werner Syndrome Helicase - metabolism
• ISSN: 0006-2960; 1520-4995; 1520-4995
• DOI: 10.1021/acs.biochem.2c00599

Werner syndrome protein (WRN) is a multifunctional enzyme with helicase, ATPase, and exonuclease activities that are necessary for numerous DNA-related transactions in the human cell. Recent studies identified WRN as a synthetic lethal target in cancers characterized by genomic microsatellite instability resulting from defects in DNA mismatch repair pathways. WRN’s helicase activity is essential for the viability of these high microsatellite instability (MSI-H) cancers and thus presents a therapeutic opportunity. To this end, we developed a multiplexed high-throughput screening assay that monitors exonuclease, ATPase, and helicase activities of full-length WRN. This screening campaign led to the discovery of 2-sulfonyl/sulfonamide pyrimidine derivatives as novel covalent inhibitors of WRN helicase activity. The compounds are specific for WRN versus other human RecQ family members and show competitive behavior with ATP. Examination of these novel chemical probes established the sulfonamide NH group as a key driver of compound potency. One of the leading compounds, H3B-960, showed consistent activities in a range of assays (IC50 = 22 nM, K D = 40 nM, K I = 32 nM), and the most potent compound identified, H3B-968, has inhibitory activity IC50 ∼ 10 nM. These kinetic properties trend toward other known covalent druglike molecules. Our work provides a new avenue for screening WRN for inhibitors that may be adaptable to different therapeutic modalities such as targeted protein degradation, as well as a proof of concept for the inhibition of WRN helicase activity by covalent molecules.